Nemolizumab is associated with improved sleep duration and fewer nocturnal awakenings in patients with prurigo nodularis

Yoshihito Mima, Masako Yamamoto, Ken Iozumi · 2026

Read Nemolizumab is associated with improved sleep duration and fewer nocturnal awakenings in patients with prurigo nodularis by Yoshihito Mima, Masako Yamamoto, Ken Iozumi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427458.txt.

Description

Yoshihito Mima, Masako Yamamoto, and Ken Iozumi report sleep gains with nemolizumab in prurigo nodularis in a 2026 retrospective study of 22 patients with refractory disease. This intensely itchy nodular skin condition wrecks sleep, mood, and social functioning, and easing itch is most patients' chief goal. Nemolizumab blocks interleukin-31 signaling involved in nerve-driven inflammation and fibrosis, dosed at 60 milligrams first then 30 milligrams monthly.

Three patients stopped by week sixteen for asthma flare, swollen redness, or acute eczema, leaving the rest for analysis of sleep duration and night awakenings beyond standard itch scales. Real-world sleep data extend trial findings for a symptom patients rank first.

Catalog record

CREATORYoshihito Mima, Masako Yamamoto, Ken Iozumi
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE9061
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13427458

Browse the full library · About the Tower of Babel